Redhill Biopharma Ltd. (RDHL) is a publicly traded Healthcare sector company. As of May 21, 2026, RDHL trades at $0.91 with a market cap of $4.85M and a P/E ratio of 0.00. RDHL moved -0.98% today. Year to date, RDHL is -34.36%; over the trailing twelve months it is -51.63%. Its 52-week range spans $0.71 to $9.25. Rallies surfaces RDHL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RedHill’s RHB-204 Matches MAP Killing of RHB-104 with Lower Doses: RHB-204 demonstrated comparable MAP killing efficacy to RHB-104 in spot and phage assays while using lower doses of two active ingredients, suggesting reduced toxicity. A Phase 2 trial in defined MAP-positive Crohn’s disease patients is planned with non-dilutive funding and potential orphan, Fast Track and QIDP designations.
| Metric | Value |
|---|---|
| Price | $0.91 |
| Market Cap | $4.85M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.25 |
| 52-Week Low | $0.71 |
| Volume | 2.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
RDHL analyst coverage data. Average price target: $0.00.